aƷQ: | HyClone̥ţѪ()HyClone̥ţѪ HyCloneĴ̥ţѪHyCloneFBSHyCloneĴFBS HyClone FBS()HyClone FBS(Ĵ)¡̥ţѪ()¡̥ţѪ¡FBS |
---|---|
ӢQ: | HyClone Fetal Bovine Serum, Characterized, Australian origin. HyClone FBS, Characterized, Australian origin. |
aƷ؛̖: | SH30084.03 |
Ѫȼ: |
Characterized FBS ȼfHyclone̥ţѪ壨Characterized FBS܉MֵͬÑ̥ţѪͨ^3100nmVĤ^VķʹѪo̥ţѪ彛^ˇăȶغѪtؙzy܉еȵļﻯW |
̎ʽ: | ˜100 nmVĤ^V |
^Դ: | Ĵ |
NԴ: | ̥ţ |
ȶˮƽ: | ≤25 EU/ml |
Ѫtˮƽ | ≤25 mg/dl |
δ | |
x | δzy |
֧ԭw | |
aƷҎ: | 500 ML |
l: | -5 to -20°C |
\ݔʽ: | ɱ\ݔ |
aƷ: |
Hyclone̥ţѪѪԴĴͨ^USDA߰ĴAQISCJCĴԭVĠIBͽṩ˃ԽLhͬrһ]čuZطڄRĿƺ@CѪԴĮaƷ|
Hyclone̥ţѪ壨Characterized FBS,Australian OriginaƷc£ ȫĮaƷԴۙѪпwȵͶLSTPgCƿcƿ֮gСIJͨ^rIUSDAJC
|
Ԫr | $1000 / ƿGE Lifesciences |
aƷDƬ |
![]() |
DƬ |
![]() |
LN۵Hyclone̥ţѪȫM1ȳFκήaƷ|} ˓Q!
WȦqqȺlͽoͷIȡMHyclone̥ţѪ b20mlԇbԇÝMُI
Hyclone¡̥ţѪʹ÷
ڼB^5%-20%̥ţѪʹõHyclone̥ţѪ10%ߝȵѪܸ׃Ļ_VӰ푺mĽY҂ڌʹ10%ĺ¡̥ţѪB293TЧdzЩҲʹ5%Hyclone FBS20%Hyclone̥ţѪҪw xmHyclone̥ţѪHyclone̥ţѪ屣淽
1ҪLڱѪ횃-20 - 70 ͜ر4бrg^1Ѫ 37̫,tѪ׃Ü,ͬrѪеЧɷ֕ƉӰѪ|һΟoһƿ, 4045mlbڟo50mlxĹѪYrweӼs10%,,Ѫڃ͜رǰAһ weg,tװlȾƿ
2һSṩѪo,o^VlFѪБҸ,tɌѪBҺһ^V,ֱ ^VѪ
3ƿbѪ:-20 -70 ͜رеѪ4ܽ1.ȻҜ,ȫ ܽٷb,һ50mloxĹܿɷb4045mlܽ^Ҏtuξ(Сɚ),ʹض cɷ־һ,pİl.ֱӌѪ-20M37,@ضȸ׃̫,ɵ| F
4ָ56, 30犼ӟȫѪ.ӟ^Ҏtuξ.˟̎ĿʹѪеaw ɷ֜.DZ,һ㲻h˟̎,̎Ѫ@,߀ӰѪ|.aw c:, ƽտs, ʴѪСጷŽM, , Mܰͼ;ɼ lWڅͻ
5Ѫеij :ҪѪе֬׃ԼѪwS,@ЩﲻӰѪ屾 |.x3000rpm,5ȥ,Ҳɲ̎ @R"Сc":^̎^Ѫ, γɕ@Щ@R^"Сc",`JѪȾһr,С cӰ푼L,Ѫ|,tֹͣʹ,Qһ̖Ѫ
Hyclone¡ѪaƷփPDFļd
Hyclone¡̥ţѪFBSaƷփHyclone¡̥ţѪf
Hyclone̥ţѪ壨¡FBSͼBxָ

ؼ̥ţѪ壨Defined FBS | ||
---|---|---|
aƷ | Ҏ | ؛̖ |
̥ţѪ壨Defined FBS, ѪԴ 40 nmo^V ȶ≤10 EU/mLѪt≤10 mg/dL |
500 mL | SH30070.03 |
̥ţѪ壨Characterized FBS | ||
aƷ | Ҏ | ؛̖ |
̥ţѪ壨Characterized FBS, ѪԴ 3 x 100 nmo^V ȶ≤25 EU/mLѪt≤25 mg/dL |
500 mL | SH30071.03 |
̥ţѪUSDACUSDA Tested FBS 3 x 100 nmo^V ȶ≤25 EU/mLѪt≤25 mg/dL ͨ^ţazyѪԴԸ˹_鶼˹R_߶ΣR |
500 mL | SH30910.03 |
̥ţѪ壨Characterized FBS, ôѪԴ 3 x 100 nmo^V ȶ≤25 EU/mLѪt≤25 mg/dL |
500 mL | SH30396.03 |
̥ţѪ壨Characterized FBS, mѪԴ 3 x 100 nmo^V ȶ≤20 EU/mLѪt≤25 mg/dL |
500 mL | SH30406.02 |
̥ţѪ壨Characterized FBS, ѪԴ 3 x 100 nmo^V ȶ≤25 EU/mLѪt≤25 mg/dL |
500 mL | SH30084.03 |
̥ţѪ壨Characterized FBS, ѪԴ 3 x 100 nmo^V ȶ≤10 EU/mLѪt≤25 mg/dL |
500 mL | SV30160.03 |
˜ʼ̥ţѪ壨Standard FBS | ||
aƷ | Ҏ | ؛̖ |
̥ţѪ壨Standard FBS, ѪԴ 3 x 100 nmo^V ȶغѪt^zyӛ ͨ^ţaBVDzy |
500 mL | SH30088.03 |
;̥ţѪ壨Specialty FBS | ||
aƷ | Ҏ | ؛̖ |
̥̿̎ţѪ壨Charcoal/Dextran Treated FBS, ѪԴ 3 x 100 nmo^V ȶ≤10 EU/mLѪt≤20 mg/dL |
500 mL | SH30068.03 |
̥ţѪ壨Dialyzed FBS ѪԴ 3 x 100 nmo^V ȶ≤10 EU/mLѪt≤10 mg/dL ≤ Mr 10 000 |
500 mL | SH30079.03 |
IgG̥ţѪ壨Super Low IgG FBS, ѪԴ 40 nmo^V ȶ≤10 EU/mLѪt≤10 mg/dL IgG: ≤ 5 μg/mL |
500 mL | SH30898.03 |
̥ţѪ壨Screened FBS | ||
aƷ | Ҏ | ؛̖ |
ES̥ţѪ壨ES Cell Screened FBS, ѪԴ 40 nmo^V ȶ≤10 EU/mLѪt≤10 mg/dL |
500 mL | SH30070.03E |
˹g|ɼ̥ţѪ壨Human Mesenchymal Stem Cell Screened FBSѪԴ 40 nmo^V ȶ≤10 EU/mLѪt≤10 mg/dL |
500 mL | SH30070.03M |
ĭh̥ţѪ壨Tetracycline Screened FBS, ѪԴ 40 nmo^V ȶ≤10 EU/mLѪt≤10 mg/dL |
500 mL | SH30070.03T |
x̥ţѪ壨Insect Cell Screened FBS, ѪԴ 40 nmo^V ȶ≤10 EU/mLѪt≤10 mg/dL |
500 mL | SH30070.03I |
СţѪ壨Bovine Calf Sera | ||
aƷ | Ҏ | ؛̖ |
СţѪ壨Bovine Calf Serum, ѪԴ 3 x 100 nmo^V ȶ≤10 EU/mLѪt≤10mg/dL 16-22Сţ |
500 mL | SH30073.03 |
aFxСţѪ壨Iron-Supplemented Bovine Calf SerumѪԴ 3 x 100 nmo^V ȶ≤10 EU/mLѪt≤10 mg/dL 16-22Сţ |
500 mL | SH30072.03 |
ţѪ壨Newborn Calf Serum, ѪԴ 3 x 100 nmo^V ȶ≤50 EU/mLѪt≤25 mg/dL Գ10ȵţ |
500 mL | SH30118.03 |
mţѪ壨New Zealand Newborn Bovine Calf Serum 3 x 100 nmo^V ȶ≤25 EU/mLѪt≤25 mg/dL Գ씵С10ţ |
500 mL | SH30401.01 |
maFxСţѪ (New Zealand Iron Supplemented Newborn Serum) 3 x 100 nmo^V ȶ≤25 EU/mLѪt≤25 mg/dL Գ씵С10ţ |
500 mL | SH30626.02 |
Ѫ壨Engineered sera | ||
aƷ | Ҏ | ؛̖ |
ţѪ壨Alpha Calf Fraction, ѪԴ 3 x 100 nmo^V ȶ≤10 EU/mLѪt≤20 mg/dL |
500 mL | SH30212.03 |
FetalClone I Ѫ壨FetalClone IѪԴ 3 x 100 nmo^V ȶ≤10 EU/mLѪt≤20 mg/dL ᘌshybridoma cells˃ |
500 mL | SH30080.03 |
FetalClone II Ѫ壨FetalClone IIѪԴ 3 x 100 nmo^V ȶ≤10 EU/mLѪt≤20 mg/dL ᘌCHO-K1CHOϵмB˃ |
500 mL | SH30066.03 |
FetalClone III Ѫ壨FetalClone IIIѪԴ 3 x 100 nmo^V ȶ≤10 EU/mLѪt≤20 mg/dL mڴּᘌwSfibroblasts ells˃ |
500 mL | SH30109.03 |
NţѪ壨Alternatives | ||
aƷ | Ҏ | ؛̖ |
LСţѪ壨Bovine Growth Serum, ѪԴ 3 x 100 nmo^V ȶ≤10 EU/mLѪt≤10 mg/dL 16-22Сţ |
500 mL | SH30541.03 |
ӏСţѪ壨Cosmic Calf Serum, ѪԴ 3 x 100 nmo^V ȶ≤10 EU/mLѪt≤10 mg/dL 16-22Сţ |
500 mL | SH30087.03 |
mӏţѪ壨New Zealand Cosmic Calf Serum 3 x 100 nmo^V ȶ≤25 EU/mLѪt≤25 mg/dL Գ씵С10ţ |
500 mL | SH30413.02 |
NخѪ壨Species-specific sera | ||
aƷ | Ҏ | ؛̖ |
wţѪ壨Donor Adult Bovine Serum, ѪԴ 3 x 100 nmo^V ȶ≤50 EU/mLѪt≤25 mg/dL Գ씵С36µijţ |
500 mL | SH30075.03 |
wRѪ壨Donor Equine SerumDonor Horse Serum, ѪԴ 3 x 100 nmo^V ȶ≤10 EU/mLѪt≤10 mg/dL Գ씵6µijR |
500 mL | SH30074.03 |
miѪ壨New Zealand Porcine Serum 3 x 200 nmo^Vݗ ȶ≤100 EU/mLѪt≤50 mg/dL Գ씵6µiji |
1000 mL | SH30908.04 |
BMedia | ||
aƷ | Ҏ | ؛̖ |
RPMI 1640 Medium with 25 mM Hepes and L-glutamine |
500 mL | SH30255 |
DMEM with high glucose, 4.0 mM L-glutamine, and sodium pyruvate |
500 mL | SH30243 |
DMEM with high glucose and 4.0 mM L-glutamine • without sodium pyruvate |
500 mL | SH30022 |
DMEM with high glucose • without L-glutamine and sodium pyruvate |
500 mL | SH30081 |
DMEM with high glucose and L-glutamine • without sodium pyruvate |
500 mL | SH30003 |
IMDM with L-glutamine and HEPES • without alpha-thioglycerol |
500 mL | SH30228 |
MEM with Earle’s balanced salt solution (EBSS) and 2.0 mM L-glutamine |
500 mL | SH30024 |
HyQTase Cell detachment solutionҺɢҺ |
100 mL | SV30030 |
Trypan Blue Solution_{ȾɫҺ 0.4% in phosphate buffered saline |
100 mL | SV30084 |
Gentamicin SolutioncùҺ 50 mg/mL |
10 x 10 mL | SV30080 |
Antibiotic Antimycotic SolutionؿҺ (Pen/strep/fungizone), 100× |
100 mL | SV30079 |
Phosphate Buffered Saline (PBS}_Һ) | 500 mL | SH30256 |
Dulbecco’s Phosphate Buffered Saline (DPBS) | 500 mL | SH30264 |
HEPES 1 M solution |
100 mL | SH30237 |
Earle’s Balanced Salt Solution (EBSSҺ) 1×, with calcium, magnesium, phenol red |
500 mL | SH30029 |
Hank’s Balanced Salt Solution (HBSSҺ) 1×, with calcium, magnesium, phenol red |
500 mL | SH30030 |
L-Glutamine 0.25% |
500 mL | SH30034 |
NEAA | 100 mL | SH30238 |
Cell Culture Grade Water oȶ(< 0.005 EU/mL), ox, ˮ, 100 nmo^V |
500 mL | SH30529 |